In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Government Drug Price Revamp Move Surprises The ABPI

This article was originally published in Scrip

Executive Summary

Less than two years after the first-ever cap on UK National Health Service drug prices was agreed, the country's Department of Health has announced it wants to change a central part of the pact on grounds it does not provide the NHS with adequate savings or price transparency.

You may also be interested in...



UK Drug Payment Plan To Save £90m Yearly Progresses Through Parliament

Legislation to align NHS statutory pricing scheme with the voluntary PPRS using a payment mechanism based on drug sales raises some industry concerns that it not be used simply as a sales tax. If it proceeds through Parliament as expected, it could take effect by mid-2017.

UK Drug Payment Plan To Save £90m Yearly Progresses Through Parliament

Legislation to align NHS statutory pricing scheme with the voluntary PPRS using a payment mechanism based on drug sales raises some industry concerns that it not be used simply as a sales tax. If it proceeds through Parliament as expected, it could take effect by mid-2017.

Brexit Vote Dismays UK Pharma, Triggers Calls To Leverage NHS As Offset

The UK now urgently needs to leverage the uniqueness of its National Health System to attract global pharma companies and offset the anti-business message contained in Thursday's Brexit vote, and the government's imminent accelerated access review needs to contain the first elements of that objective, according to the Association of the British Pharmaceutical Industry.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel